QuantiFERON (R)-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guerin (BCG)-vaccinated country: the HUR-BIO single-center real-life results

ŞEYHOĞLU E., UYAROĞLU O. A., ERDEN A., KILIÇ L., KARADAĞ Ö., AKDOĞAN A., ...Daha Fazla

CLINICAL RHEUMATOLOGY, cilt.40, sa.5, ss.2027-2035, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s10067-020-05443-3
  • Dergi Adı: CLINICAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.2027-2035
  • Anahtar Kelimeler: Anti-TNF-alpha drugs, BCG, Latent tuberculosis, QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test, Tuberculin skin test (TST), GAMMA RELEASE ASSAYS, INFECTION, RISK, ANTAGONISTS, GUIDELINES, DIAGNOSIS
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives The Turkish population is vaccinated with Bacille Calmette-Guerin (BCG), and the BCG vaccination decreases the specificity of the tuberculin skin test (TST). The purpose of this study was to investigate the incidence of active tuberculosis (TBC) among rheumatic patients who were screened only with the QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test for latent TBC prior to biological treatment.